Inhibition of STAT3/5 activity by MCL with a distinct contribution from ruxolitinib, enhances blockage of JAK/STAT signaling in MPNs, thereby improving the therapeutic efficacies of ruxolitinib (including reducing splenomegaly and serum cytokines). This evidence concerns the gene SOAT1 and mantle cell lymphoma.